Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review
2018
ABSTRACTIntroduction: High prices of second-generation direct-acting antivirals (DAAs) in the treatment of chronic hepatitis C virus (HCV) patients led to reimbursement decisions based on cost per quality-adjusted life year (QALY).Areas covered: We performed a systematic review of cost-utility analyses (CUA) comparing interventions with second-generation DAA therapies with no treatment, and with previous therapies for chronic HCV patients until July 2017. A total of 36 studies were included: 30 studies from the perspective of the healthcare payer, 3 from the societal perspective, and 3 did not report the perspective. For genotype 1, the highest number of ICER comparison corresponds to sofosbuvir (SOF) triple therapy and SOF-based combinations which reported a cost per QALY systematically ranging from negative to lower than US$100,000 when compared with no treatment or dual therapy or Simeprevir triple therapy.Expert commentary: Selected studies may be overestimating the true cost per QALY of second-genera...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
53
References
11
Citations
NaN
KQI